Home / Transcripts / Auna S.A. (AUNA) · November 18, 2026

Auna S.A. (AUNA) Earnings Call Transcript

November 18, 2026

New York Stock Exchange US Health Care Health Care Providers and Services earnings 55 min

Earnings Call Speaker Segments

Ana Maria Mora executive
#1

Thanks very much, operator. Good morning, everyone, and thanks for joining Auna's conference call, where we'll go over the results for our third quarter. I'd like to point out that a webcast presentation accompanies today's discussion. Should you require a copy of that presentation, it's available on our Investor Relations website, or you can reach out to Auna's Investor Relations team. Also note that in discussing variances, we'll do so comparing against the prior year and using FX-neutral or local currency terms for Mexico and Colombia, unless we say otherwise. Turning to Slide 2. Alongside reporting unaudited financial results prepared under International Financial Reporting Standards, we will cover certain non-IFRS financial measures and operating metrics, foreign exchange neutral calculations among them. Investors ought to review carefully the definitions of these measures, the metrics and reconciliations contained in our earnings press release, which was published yesterday after market close, so that they understand them properly. Non-IFRS financial measures and operating metrics should not be viewed on their own, nor as a replacement for or better than IFRS financial measures, and they are supplied purely as supplemental information. Before our remarks get underway, please also be aware that some statements we make during today's discussion could be forward-looking statements, built on management's present expectations and beliefs and subject to numerous risks and uncertainties that might cause actual results to differ materially, including factors potentially outside the company's control. Among these are, without limitation, our guidance for revenue, Adjusted EBITDA and capital expenditure, our target leverage ratio, the outcomes of key initiatives we are carrying out in Mexico, Colombia and Peru, the timeline for building and starting operations at Centro Ambulatorio Trecca, the capacity and market expected for Centro Ambulatorio Trecca once constructed, our capacity to recover any loss under the oncology risk-sharing contract in Colombia, how our strategic plan is executed, our planned investments, our anticipated revenue growth and adjusted EBITDA growth, the expected effect of regulatory price caps in Colombia, and the generation of further growth and sustainable value for all stakeholders. To learn about the risks that could affect our forward-looking statements, please see our Form 20-F filing with the U.S. Securities and Exchange Commission together with our earnings press release. Slide 3, please. Joining us on today's call are Jesus Zamora, our Executive Chairman and President; Gisele Remy, our Chief Financial Officer and Executive Vice President; and Lorenzo Massart, our Executive Vice President of Strategy and Equity Capital Markets. They'll walk through Auna's consolidated and segment financial and operating results for the quarter and give an update on the various strategic growth initiatives we're pursuing. Following that, we'll open things up for your questions. Jesus, over to you.

Jesús Zamora Leon executive
#2

Thanks, Annie. Let's start on Slide 4. During the third quarter, we kept up our growth momentum throughout Auna's regional platform, posting top-line growth of 10% on an FX-neutral basis. Especially encouraging was the pick-up in growth in Mexico, along with better profitability and its first quarter of year-over-year adjusted EBITDA growth in 2026, marking the fourth quarter in a row of growth. In Colombia, profitability came under pressure from significant medical costs under a specific oncology risk-sharing contract and drug pricing caps. Importantly, the underlying business kept showing strong momentum, delivering a third consecutive quarter of robust revenue growth, backed by more high-complexity care. We took firm action to tackle the situation, and we'll cover this specific contract in more depth during today's presentation. Penalties connected to reconciling receivables from prior years in Peru also weighed on third quarter profitability. The fundamental strength and growth potential of our Peru segment remain intact, and we continue to see substantial opportunities stemming from our strategic emphasis on high-complexity care and other growth initiatives in this market. We maintained robust cash generation, fueled by disciplined working capital management and improved cash conversion, which directly underpins our ongoing deleveraging efforts. Let's move to Slide 5. This marks the third quarter in a row where we've posted solid revenue gains, and free cash flow for the year to date is up 95% compared with a year earlier—both signs that our platform's underlying fundamentals remain sturdy. That powerful cash generation helped us bring our leverage ratio down sequentially to 3.5x, which puts us nearer the 3x medium-term goal we've set. The same underlying strength comes through in the operating metrics shown at the bottom of this slide. Across our healthcare services network, total capacity utilization on a year-to-date basis climbed versus a year ago to 68%, which speaks to steady gains in utilization throughout the platform. For Mexico, total capacity utilization during the quarter was up 2 percentage points year over year. In Peru, total plan memberships continue to expand, and Oncosalud's oncology MLR came in at 50.7%. Those patterns, along with the operating metrics for the quarter that we released last month, strengthen how much we believe in our integrated healthcare model and the AunaWay; our confidence holds in the medium- to long-term upside of our regional platform, which keeps growing in scale and integration. Turning to Slide 7, we can examine more closely how we performed in Mexico. Mexico's top line sped up and profitability recovered, driven by growth in surgery volumes, which rose 12% year-over-year, and in chemotherapy and radiotherapy sessions, which were up 34%. These patterns demonstrate that the AunaWay and our strategy keep building momentum in Mexico, a market that is key to Auna's long-term growth. Even though new VAT deductibility rules created sector-wide challenges for our insurance operations in Mexico, the Monterrey Healthcare network’s strong performance and higher volumes more than made up for those effects, which let the Mexico segment’s Adjusted EBITDA get back to growth compared with a year earlier. Although the VAT change affected Mexico’s insurance market, we are still enthusiastic about what lies ahead in the B2B segment through Auna Seguros, as we build on the position we have already established and our effective sales channels in dental and vision insurance. In addition, our confidence in the long-term promise of oncology insurance in Mexico has not changed. We believe there are substantial opportunities to expand this product, deepen Auna’s vertical integration, and widen access to our value-based care model in that market. Now please turn to Slide 8. In Peru, top-line growth came from a 21% increase in surgery volumes and an 18% rise in chemotherapy and radiotherapy sessions, reflecting our continued emphasis on high-complexity procedures across the network. Another factor was our tighter focus on B2B accounts, which carry better retention thanks to Oncosalud's multichannel access model. For instance, having signed 2 new corporate agreements, we anticipate adding about 4,000 plan members in the fourth quarter. Peru's profitability in the quarter was pressured by the onboarding of new B2B accounts that have not yet reached normalized utilization levels, together with higher pharmacy and clinical payroll expenses related to greater hospitalization and emergency volumes. We also took a hit from penalties tied to reconciling receivables from earlier years, and those items contributed to a 6% drop in consolidated Peru Adjusted EBITDA. If you set aside the billing-related penalties, Adjusted EBITDA would have been roughly flat compared with a year ago. Turning to Slide 9: the basic drivers of our Colombia business remained solid. Last quarter we told you about adding ICU and hospitalization capacity at IMAT Oncomédica in Montería to meet growing need for high-complexity care. We also broadened our mix of payors, with revenue from private payors rising and our exposure to government-intervened payors coming down further. Colombia's revenues in local currency rose 12%, yet segment Adjusted EBITDA declined 30%, largely because of two factors. To start, we saw unusually high medical costs tied to a particular oncology risk-sharing agreement, which accounted for roughly 4% of revenues in Colombia. That agreement involved about 500,000 lives, and advanced-stage cancer cases occurred at a much greater rate than we had expected, which drove treatment expenses well beyond what the contract had assumed. We have ended that contract since then in order to cap further exposure, and we have brought in legal counsel to examine every avenue for recovery available under it. Next, price caps set by regulators beginning in mid-August weighed on the third quarter and will keep affecting the fourth quarter as we put operational changes in place to rein in this cost increase. Cost pressures in Colombia—like higher staffing expenses from required wage hikes and the legally mandated shorter workweek we’ve talked about in earlier quarters—kept dragging on our results there. To offset that effect, we’re staying focused on actively managing revenue mix and our payor portfolio, along with efforts to boost operating efficiency throughout our Colombian network, aiming to restore our structural margins. Although these headwinds have weighed on near-term results, our top priority is still making contract economics stronger and capitalizing on growth opportunities across our Colombian healthcare network. I’ll now hand the call to Gisele, who will go through our results in more detail.

Gisele Ferrero executive
#3

Appreciate it, Jesus, and good morning to all of you. Let's please move to Slide 11 now. Our strategic emphasis on providing more high-complexity services along with value-based care kept fueling revenue growth throughout our regional platform in the third quarter. In Mexico, surgery volumes rose 12% and oncology services rose 34%, and together these drove a 2.9 percentage point gain in total capacity utilization, which climbed to 41%. In Peru, where Auna operates in a vertically integrated way, surgeries rose an impressive 21%, and average monthly revenue per membership plan was up 5%, which shows our strategy is working to bring on high-quality corporate B2B accounts, keep more profitable members and hold disciplined pricing across our plans. Turning to Colombia, we continued to gain more ground in the private segment, as revenue from private payors climbed 22% during the quarter. Additional growth came from bringing ICU beds back into service and from adding hospital beds in Montería. Now let's turn to Adjusted EBITDA on Slide 12. The bridge on that slide illustrates that our consolidated EBITDA is shaped by 3 separate, quantifiable drivers. On the positive side, first, Mexico posted 5% year-on-year growth in Adjusted EBITDA, showing the operating leverage that we are beginning to realize in that market. In particular, Adjusted EBITDA at the Monterrey healthcare network increased 10% year-on-year, which helped offset weaker results at Auna Seguros stemming from the sector-wide shift in VAT deductibility. That said, two unusual items in Colombia and Peru briefly canceled out this fundamental growth. In Peru, our results took on PEN 18 million of revenue adjustments, mostly related to billing issues from earlier years. If you set aside the net effect of those revenue adjustments, EBITDA would have been roughly flat compared with a year ago. As we have noted previously, our internal billing cycle keeps getting better, and that gives us protection against this kind of hit to the revenue billings we produce going forward. So because of that, most of these effects should be absorbed over the next few quarters, which clears the path for Peru's EBITDA margins to return to their historical low-20s levels. In Colombia, results took a hit from the specific oncology risk-sharing contract we mentioned earlier, where treatment costs came in well above the contractual assumptions, along with new regulatory price caps on high-cost oncology medicines. We've successfully ended that unprofitable contract, which accounted for roughly 4% of Colombia's revenue, so this near-term headwind is now effectively gone. Also worth noting: the price caps only had a partial impact in the third quarter, since they took effect midway through the period. Let's move on to Slide 13 now, please. Adjusted Net Income came in lower than it did in the third quarter of 2025, and the reason is accounting effects, not how our operations performed on a cash basis. To be specific, the drop is because we didn't have the PEN 40 million non-cash FX gain this time around — we booked that gain in the same period a year earlier. That's consistent with what we've said in earlier quarters: after the refinancing we completed most recently, in the fourth quarter of 2025, we reset the levels on our FX hedges. As a result, FX variances should be pretty small going forward and should only show up if the U.S. dollar moves outside the 3.4 to 3.8 range. If you exclude FX effects together with the non-cash impact from the future purchase obligation tied to IMAT Oncomédica, our underlying net finance costs in fact came in better versus a year earlier. Our blended interest rate at present, which takes in hedges and mostly local currency funding, sits at 10.38% year-to-date. Another meaningful positive swing this quarter came from a PEN 20 million reduction in income tax expenses. Please turn with me to cash flow on Slide 14; we keep driving better cash conversion through stronger collections and a lower net tax payment throughout our platform. Year-to-date, net operating cash flow rose 62% to PEN 713 million, and free cash flow jumped 95% to PEN 626 million. That robust result came from disciplined working capital management, in particular better collections and fewer accounts receivable days in Peru and Mexico, plus stable collections in Colombia, along with lower tax payments. Across the 9-month period, our cash conversion cycle went from negative 9 days in 2025 to negative 15 days, which lets us keep producing cash via active working capital management. Year-to-date, our cash position grew 83% to PEN 614 million, which keeps us on track for our medium-term leverage target of 3x. Last, at 3% of revenue, our CapEx stayed comfortably under our 4% full-year guidance. Moving to Slide 15 for our debt profile: aside from the slight net debt leverage gain driven by Auna's growing cash flow, note that gross debt declined PEN 7 million FX-neutral, an improvement masked by sol depreciation versus the U.S. dollar, which added PEN 90 million since year-end 2025. We ended the third quarter with $194 million in credit lines, of which slightly more than $134 million remained undrawn. Also note that local currencies account for 54% of our debt, and 85% of the U.S. dollar-denominated balance is hedged against the Peruvian sol. On top of that, hedging covers 75% of the floating-rate interest on our Mexican debt too. Last, of the PEN 481 million in gross debt coming due over the next twelve months, PEN 216 million is revolving working capital debt, which is renewed when it matures and is well covered by the USD 194 million of credit lines I mentioned earlier. Beyond that, PEN 165 million consists of short-term maturities under our 2030 term loan, which the PEN 614 million cash balance we held at the end of the third quarter covers comfortably as well. The remainder is made up of other near-term maturities tied to long-term borrowings, plus accrued interest on the 2029 and 2032 bonds we have outstanding. That concludes my review. I'll return the floor to Jesus now for some final comments, and after that we'll take your questions.

Jesús Zamora Leon executive
#4

Thanks, Gisele. Matching what we told you back in October and what we said in yesterday's earnings release, we continue to anticipate that revenue growth for the full year 2026 will come in within the 10% to 14% guidance range on an FX-neutral basis. As for adjusted EBITDA, we anticipate it will remain broadly flat or edge down somewhat compared with the prior year. The main drivers there are the unusually large medical costs associated with the terminated oncology contract in Colombia, plus the impact of regulatory price caps on selected high-cost oncology medications. On capital expenditure, our guidance is likewise unchanged, at approximately 4% of consolidated revenues. Peru is a market where our integrated model already operates at scale, and we anticipate seizing the substantial remaining growth opportunities there. Our emphasis will be on broadening high-complexity services past oncology into areas such as neurosurgery, traumatology and orthopedics, and cardiovascular surgery; as the onboarding of new B2B accounts normalizes, we expect profitability to improve. Mexico is now positioned well for sustained growth and better profitability, backed by improved payor classifications, ongoing physician onboarding, expansion of our oncology franchise and rising surgical volumes. Mexico has also maintained its growth momentum through the fourth quarter so far. Although regulatory and operating cost pressures we mentioned earlier keep us cautious about Colombia in the near term, that market is still a core piece of our regional platform. With high-complexity care continuing to expand in Montería and our PGP arrangements, we expect Colombia to recover gradually and become a meaningful contributor to profitable growth once again. And lastly, our strong free cash flow generation allows us to keep reinforcing the balance sheet and to move closer to our medium-term leverage target of 3x. Before we take questions, I'd like to stress that even as we work through these near-term headwinds, we have full confidence in the long-term potential of our regional platform, our integrated care model and our market-specific strategies. We stay committed to speeding up expansion in Mexico, bringing profitability back in Colombia, enhancing earnings quality plus operating efficiency in Peru, and converting our commercial momentum into stronger cash generation while increasing sustainable shareholder returns. Operator, kindly begin the question-and-answer portion of the call.

Mauricio Cepeda analyst
#5

There are two things we'd like to ask. First, about Colombia. Given that you ran into this kind of unfavorable situation on that specific contract, are other contracts exposed to similar pressure too? And how would that affect your willingness going forward to grow these risk-sharing partnerships? Or how would it affect the kinds of protections you'd insist on in the contracts? That's our first question. The second concerns Mexico: now that capacity utilization is improving, what do you view as a realistic longer-term utilization target for the existing hospital base? And what EBITDA margin could you achieve if you factor in the operating leverage under your current payor mix?

Jesús Zamora Leon executive
#6

Great. Thank you so much, Mauricio. It's always a pleasure to have your questions among the first in our quarterly results review. We appreciate it. On Colombia, I'd say we don't believe that what happened with one of our PGP contracts, a newer one, carries any contagion effect or any replicability across the rest of our PGPs and PIPs contracts; so we don't see it as a sector issue; it's a very specific one-off, single-contract situation; and we believe we've taken action on it. As for the broader question, yes, as we look at Colombia, of course, Colombia gives us a huge healthcare market, given its universal healthcare sector. But for us specifically, it provides an opportunity to capture a larger market share of high-capacity pockets of value. That's very important; but we are — and this is something we're pursuing aggressively. But of course, it has come with too much sectoral risk. And we will resolve this with urgency. Those, I'd say, are my points on Colombia. I don't know, Gisele, whether you want to add anything else on Colombia, and then I can move on to Mexico.

Gisele Ferrero executive
#7

Yes, and thank you, Mauricio, for that question. This is very much consistent with what Jesus already said: the negative impact from the oncology risk-sharing contract in Colombia came specifically from the high level of cost execution on that contract. Since we've also gotten some questions about quantifying these effects, I wanted to add some color. Of the $4 million decline in Colombia's EBITDA compared with the third quarter of last year, we estimate that roughly 70% came specifically from this oncology risk-sharing contract, which has now been terminated. The other 30% stems from the price caps on high-cost medicines in Colombia that were mentioned earlier. So those price caps will keep affecting us in the fourth quarter, across the 3-month period of the fourth quarter. It was only 30% in the third quarter because, as I mentioned, it was halfway through, but we will see that impact across the 3 months of the fourth quarter. And sorry, Jesus, you were about to move on to the Mexico question.

Jesús Zamora Leon executive
#8

Yes. Sorry, I failed to unmute myself, so that was quite long-winded, but let me try to condense it. Thank you, Mauricio. And thank you, Gisele, for the extra point about Colombia; so regarding Mexico, as you can see, momentum keeps building. This quarter, of course, was the first one with year-over-year growth. It's really important to put this in context in a very tough year for the insurance market in Mexico, where the VAT has reduced the number of policyholders in Mexico. That's something that hadn't happened in 15 years. So it matters a lot, and we're growing. So even though the market has contracted by something like 1 million policies, we are growing; and I see growth coming from greater intimacy with payors, recognition that we can contain costs and grow volume, especially in higher complexity. And of course you can see that with our contract with ISSSTELEON, which again highlights the confidence in our ability to deliver great service at the appropriate cost. You can see that in the growth in chemotherapy and radiotherapy in surgeries, you can see all of those growing. And we are clearly acting on the levers so that margins keep recovering as utilization rises. You asked specifically about utilization. We see utilization growth in our chemotherapy treatment centers and, of course, the new machine that we now have in the radiotherapy center and beds as well, but slowly, slowly. I believe we can add 2 or 3 percentage points a year and still have increasing margin growth; and that's very important. So it isn't just about volume. It's about how you grow and keep good margins. So I think our thesis in Mexico hasn't changed. The underlying market opportunity is really interesting. It remains interesting, notwithstanding this huge sector change with the VAT. So I think that would be my answer on Mexico. On EBITDA margins, I can just say, Mauricio, that given the inflection point you've seen in volumes and given that this is a scale business, you will see us recover the EBITDA margins we've had in the past and that can support a growing business, a growing and much more profitable business in Mexico; we're excited about Mexico. Gisele, would you like to add something on that?

Gisele Ferrero executive
#9

Right, so the margin recovery we've been seeing in Mexico over the last few quarters strikes me as particularly encouraging, not just given the market backdrop, but also when we take into account that behind that 26% EBITDA margin specifically, the healthcare network in Monterrey is sitting at a 28% EBITDA margin with occupancy levels of 41%. So I think as that occupancy ramp-up keeps progressing, we'll keep seeing favorable effects on that EBITDA margin. And we're quite optimistic about how that volume growth will evolve over the coming quarters.

Jesús Zamora Leon executive
#10

Yes, and I’d also mention that 80% of our payor relationships have now confirmed the tiers we currently operate in, which represents a bigger population covered by insurance. That’s really important; we have a very stable base of payors and, of course, payor patient volumes. I’d add as well that out-of-pocket is growing nicely. Not long ago it was around 6% of revenues; now we’re close to 9%, and we could envision possibly doubling that. And Mexico has one of the highest out-of-pocket payors—families and individuals—in the world. So we view that as a great opportunity to also make an impact on capacity utilization.

Ana Maria Mora executive
#11

Thank you, operator. Good morning, everyone. Thanks for joining. The first question comes from < > and it is, what are the plans for the rundown of Auna's 2029 bonds?

Gisele Ferrero executive
#12

Thanks for the question, and to answer it briefly: roughly $100 million of the 2029 bonds is still outstanding, and those mature in 3 years, near the end of 2029; the bonds can be called at the close of this year at 105%. So what I'd say is that Auna is always looking at market opportunities so that its capital structure stays as efficient as possible. We still have over 3 years to deal with that maturity, but of course we keep assessing the best options for refinancing that amount.

Ana Maria Mora executive
#13

Thanks, Gisele. Just a moment. Our next question is from < >, who asks whether any negative effect on the EBITDA margin is anticipated for 4Q '26 as a result of the headwinds that were felt in 3Q '26.

Gisele Ferrero executive
#14

I can take that question first if you have anything else to add. Among the headwinds we discussed in the third quarter, as we mentioned earlier and also noted in our updated guidance, impacts will keep affecting the fourth quarter from the billing matters in Peru and the price caps in Colombia. Mexico's business will keep recovering in the fourth quarter, and we will keep seeing EBITDA growth in the fourth quarter for Mexico's EBITDA. I think it's also worth noting that in Peru's case, as we said earlier, operating KPIs and operating trends remain very, very positive. Cash flow generation has improved substantially because we've been able to shorten the internal billing cycle and improve cash flow conversion thanks to better collections. So we will face these 2 margin pressures from the billing matters in Peru and the price caps in Colombia. However, operating trends in the fourth quarter and going into next year remain positive, and that is what will bring us to margin recovery in the coming quarters.

Jesús Zamora Leon executive
#15

Right. And Gisele, I'd like to add that, in a more directional sense, 2026 has been — and this quarter especially has been — marked by truly extraordinary, unexpected hits to our results. And although we're obviously working on the quantitative figures for the remainder of this year and for next year, it matters that you also recognize we're addressing the qualitative side of predictability. We can't be defined by these exogenous events. We have to ensure that, above all, we hold complete control over what we're doing in the services we deliver; and there's a strong opportunity for us, including in Colombia, which always carries a quarterly headline — not a surprise, I'd say, but a headline. So I believe we're proceeding with real precision and putting together a deliberate plan to tackle the qualitative dimension of our results. That dimension is predictability. We want the investor community to see us delivering with no surprises. These quarters, as I describe them, have been dirty quarters with plenty of extraordinary events; that's on our agenda. We intend to tackle it.

Ana Maria Mora executive
#16

All right. The following question concerns Oncosalud. What headwinds are you facing there? Is its growth running below last year's pace?

Jesús Zamora Leon executive
#17

So overall, in Peru there are several factors at work that are generating some net decreases in our population base. But generally speaking, Oncosalud is viewed as a single product, when in reality it consists of many different products at varying price points. And on top of that, we now offer different coverages for other high complexity care as well as limited general healthcare coverage. I don't think this is really a matter of headwinds. What it comes down to is how we address a market that trusts the Oncosalud brand within a segment that has only a limited amount of disposable income to put toward healthcare, toward the healthcare expense burden of the family. I don't believe there's anything specific that must be done; we need to keep doing what we have done for decades now to ensure we have an affordable product that covers ailments well, particularly prevention and early detection, and of course produces those high survival rates at a price people can access. I don't think there are any headwinds in particular, just small commercial actions that are needed to keep growing our covered population.

Ana Maria Mora executive
#18

Thank you, Gisele. Staying with Peru for a moment, there's another question from < >, and what he wants to know is this: given that hospitals in Peru are running at 90% utilization, how do you view the potential for volume growth from this point?

Jesús Zamora Leon executive
#19

Well, again, our focus is so much on high complexity that measuring beds isn’t always the most suitable approach; and as you may have noticed from what we’ve reported previously, we are constructing a site in the south of Lima that deals with capacity utilization. And even more importantly, we’re increasingly doing more in high-complexity outpatient services. And I think that represents a key strategic direction for how we build capacity. And I think some of the research analysts have consistently published our asset-light strategy; so there’s no need for us to build these enormous hospitals that we have everywhere. We can actually just build asset-light facilities marginally that can deliver services for hundreds of patients and family members a day without huge investments. And that’s — you will see us pushing that lever aggressively in — particularly in Peru and Colombia.

Ana Maria Mora executive
#20

Thanks, Jesus. Moving on to the next question...

Jesús Zamora Leon executive
#21

My apologies, Annie, sorry about that. I simply want to confirm we feel good about this. I neglected to address this portion. At 90% capacity utilization, we are comfortable. Our hospitals operate at those levels; and once they go beyond that, it immediately triggers a need to take action on the asset-light expansion, just as I said earlier. I just wanted to make that clear.

Ana Maria Mora executive
#22

Thanks, Jesus. Staying with Peru, there are a few questions from < >. He's asking when the billing problems in Peru will be resolved. Then, on Mexico, my understanding is that the VAT issues there will settle down, since they affect everyone. Is that right? Will overall demand end up lower because of that? And last, is there any update on the strategic MOU?

Jesús Zamora Leon executive
#23

All right. I’ll take the second one so I can hand things over to you, Gisele. Now, regarding VAT in Mexico, it ought to be viewed from a different angle. Sure, everyone is affected by it. Everyone is affected, yes, but it actually works in favor of those of us whose cost point for insurance payors is the most attractive; that’s the reason you’re seeing growth from us. Yes, it affects everyone. Even so, we have a price point that insurance companies find very appealing, and we are growing. I believe we’ve kept doing that despite the pressures coming from the insurance companies. And the first question concerned Peru, and Gisele, it was about revenue reconciliation; and the third question concerned surges, I think, correct?

Gisele Ferrero executive
#24

Right, and just to address the Peru question briefly — when do we expect those billing issues there to normalize? As I said before, we've seen really substantial gains in the internal billing cycle. And, as we noted in earlier quarters, we're still negotiating reconciliations for prior periods, and that's the reason these effects keep showing up in upcoming quarters; we do expect to be able to reflect the impacts tied to previous periods over the next few quarters and then get those effects normalized toward the second half of 2027.

Jesús Zamora Leon executive
#25

On Sojitz, we're moving along well. With respect to our relationship with Sojitz, we expect to have something early in the year, maybe an announcement. Partnering with them is exciting for us, and they have such a credible healthcare footprint in other regions. It's still early for us to say much about it, though we are excited about that venture.

Ana Maria Mora executive
#26

All right, and moving on — well, this is a bit of a detour from Peru, but I want to talk about Torre Trecca. Someone asked whether you could walk us through what happens next with the Torre Trecca project.

Jesús Zamora Leon executive
#27

The encouraging part is that the Torre Trecca project, the Centro Ambulatorio Trecca, remains on schedule. About a week or 2 weeks back, we actually made the first construction payment. President Fujimori also visited the site less than 2 weeks ago, and the Head of EsSalud, the Social Security in Peru, came as well. So we believe we are on time, and we don't foresee any surprises on that project in the near future. We're very excited, and the government is very excited too. I think we can make a huge difference, just as we have for other populations we serve. This project matters a great deal, not because of its size, but because it will demonstrate Auna's capabilities in the B2G, B2 government sector, which in Mexico and Peru especially is a high multiple, 5x, 6x, of the private sector market. So we're really excited about this and about where it can take us in B2G and PPP projects across the region. Thank you very much for that question.

Ana Maria Mora executive
#28

Thanks, Jesus. As we approach the last questions, there’s one about Mexico, and after that we’ll get to El Niño. So on Mexico, this came from < >. Could you provide more detail on how much of 3Q was affected by the 16% revenue increase for the ISSSTELEON B2B agreement at OCA? And in Mexico, excluding that related revenue growth, what would there be?

Gisele Ferrero executive
#29

Right, and thank you. As we noted during earlier quarters, one factor behind the volume and margin recovery in 2026 has been the renewal of the ISSSTELEON contract late last year and into the start of this one, on improved terms. So clearly that also meant we took in more volume compared with the same period a year ago. And as Jesus mentioned, we expect to keep seeing our B2G segment, in Mexico and particularly Monterrey, make a positive contribution to our revenue mix, and it's a segment we're very keen to grow in the years ahead as well.

Ana Maria Mora executive
#30

Thank you, Gisele. And last up in the queue, we have a question about El Niño potential — that phenomenon — and what impact it could have. Could you talk about how we plan to keep infrastructure continuity going and support the medicine supply?

Gisele Ferrero executive
#31

Right, thanks Annie. As we noted during our Investor Day too, forecasts point to a strong to extremely strong El Niño arriving late this year and early next year, and the weather is something that can be highly unpredictable. Because of that, we have put a plan into action that is dedicated to pushing forward various actions so that operational continuity is assured and the safety of our patients and our staff is ensured; along those lines, we are reinforcing infrastructures. We are securing critical supply of various medications and other types of supplies. And we are making certain we hold backup supplies of fuel, water, electricity and our own generators, both sets of backup generators, making sure patients have pre-organized flows back and forth between the places we need, and also continuing to guarantee flows between Northern Peru and Lima and between Arequipa and Lima; so this is being done not only for Piura, Chiclayo and Trujillo, where the impact will probably be greatest, but in Arequipa and Lima as well, so right across our entire Peru network. We are doing this as efficiently as we can, but again, making sure we cover things and that our patients will be well taken care of, while also ensuring our staff's safety.

Ana Maria Mora executive
#32

All right. Thanks, Gisele. With that, I believe we've now reached the end of the question queue for today. So thank you everyone for the time and for taking part. And Jesus, let me turn it back over to you for some closing thoughts.

Jesús Zamora Leon executive
#33

Thank you, Annie. Before I share my closing thoughts, I just want to add that we're as ready as anyone could possibly be for El Niño—better prepared than at any point over the past 10 years when we've had Niño. So we understand what has to be done, and we've built plenty of cushions to ensure our populations and our clinical staff are well protected during Niño events. I'd also like to point out—and I'm not sure whether this fits the call—that we had a very important, I'd call it blessed, visit from the Pope in Peru over these past couple of days. And we were fortunate enough to ensure that if anything happened to him, he'd be safe and healthy at the site through Auna. So we covered his visit with Auna staff and Auna ambulances. And I mention this because it shows—it should show the investor community the capabilities we have to sustain a service offering that is unique, that is unique. El Niño is unique. The Pope's visit is unique. Some of those masses drew 2 million people. And I think that should give the investor community yet another indicator of how we operate. Now, for my closing remarks, I want to be very clear. It's been a tough quarter. It's been a very tough quarter. Colombia is, of course, concerning, but we're on it; and I want to make it very clear, we're on it; we have a great team led by Rayet Harb, and that gives me comfort. We will turn the page on the current challenges; and Mexico and Peru are on the right track and gaining momentum. So we're very enthused about that; we want to thank you for the support. Thank you for your attention; and with that, I'd like to close the session. Thank you very much.

Operator operator
#34

This concludes today's conference. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Auna S.A. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Auna S.A. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.